Next Article in Journal
Snakebite: When the Human Touch Becomes a Bad Touch
Next Article in Special Issue
Botulinum Neurotoxin Injection for the Treatment of Recurrent Temporomandibular Joint Dislocation with and without Neurogenic Muscular Hyperactivity
Previous Article in Journal
Analysis of the Relationship between Alternative Respiration and Sterigmatocystin Formation in Aspergillus nidulans
Previous Article in Special Issue
Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome
Open AccessReview

Therapeutic Approaches of Botulinum Toxin in Gynecology

Department of Medical and Surgical Specialties, Faculty of Medicine, Transilvania University of Brasov, Brasov 500019, Romania
Department of Fundamental Disciplines and Clinical Prevention, Faculty of Medicine, Transilvania University of Brasov, Brasov 500019, Romania
Clinical Department of Obstetrics and Gynecology, The Carol Davila University of Medicine and Pharmacy, Bucharest 020021, Romania
Author to whom correspondence should be addressed.
Toxins 2018, 10(4), 169;
Received: 31 March 2018 / Revised: 18 April 2018 / Accepted: 19 April 2018 / Published: 21 April 2018
Botulinum toxins (BoNTs) are produced by several anaerobic species of the genus Clostridium and, although they were originally considered lethal toxins, today they find their usefulness in the treatment of a wide range of pathologies in various medical specialties. Botulinum neurotoxin has been identified in seven different isoforms (BoNT-A, BoNT-B, BoNT-C, BoNT-D, BoNT-E, BoNT-F, and BoNT-G). Neurotoxigenic Clostridia can produce more than 40 different BoNT subtypes and, recently, a new BoNT serotype (BoNT-X) has been reported in some studies. BoNT-X has not been shown to actually be an active neurotoxin despite its catalytically active LC, so it should be described as a putative eighth serotype. The mechanism of action of the serotypes is similar: they inhibit the release of acetylcholine from the nerve endings but their therapeutically potency varies. Botulinum toxin type A (BoNT-A) is the most studied serotype for therapeutic purposes. Regarding the gynecological pathology, a series of studies based on the efficiency of its use in the treatment of refractory myofascial pelvic pain, vaginism, dyspareunia, vulvodynia and overactive bladder or urinary incontinence have been reported. The current study is a review of the literature regarding the efficiency of BoNT-A in the gynecological pathology and on the long and short-term effects of its administration. View Full-Text
Keywords: botulinum toxin; chronic pelvic pain; overactive detrusor; vaginism botulinum toxin; chronic pelvic pain; overactive detrusor; vaginism
Show Figures

Figure 1

MDPI and ACS Style

Moga, M.A.; Dimienescu, O.G.; Bălan, A.; Scârneciu, I.; Barabaș, B.; Pleș, L. Therapeutic Approaches of Botulinum Toxin in Gynecology. Toxins 2018, 10, 169.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

Back to TopTop